Vi­a­tris and Mapi eval­u­ate next steps af­ter FDA re­jects long-act­ing MS in­jec­tion

The FDA hand­ed down a com­plete re­sponse let­ter to Vi­a­tris and Mapi Phar­ma for their long-act­ing in­jec­tion for the treat­ment of re­laps­ing forms of mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.